Hospital Practice
ISSN: 2154-8331 (Print) 2377-1003 (Online) Journal homepage: http://www.tandfonline.com/loi/ihop20
Letters To The Editor Lazar J. Greenfield M.D. , Sheldon Rudansky M.D., Robert F. Sacha D.O., R. Sobocinski M.D. & J. A. Stankiewicz M.D. To cite this article: Lazar J. Greenfield M.D. , Sheldon Rudansky M.D., Robert F. Sacha D.O., R. Sobocinski M.D. & J. A. Stankiewicz M.D. (1992) Letters To The Editor, Hospital Practice, 27:12, 16-16, DOI: 10.1080/21548331.1992.11705532 To link to this article: http://dx.doi.org/10.1080/21548331.1992.11705532
Published online: 17 May 2016.
Submit your article to this journal
View related articles
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ihop20 Download by: [Monash University Library]
Date: 02 July 2016, At: 21:43
Letters to the Editor Antiembolic Filters: The State ofthe Art
Downloaded by [Monash University Library] at 21:43 02 July 2016
''A Non classic Case of Pulmo-
nary Embolism," by Elliot Rapaport (HP, September 15) contains a lot of useful information but unfortunately also contains some misinformation. In the discussion of follow-up, Rapaport mentions the use of an "umbrella" filter, which was the term applied to the MabinUddin device. It has not been marketed since the mid-1980s, because it became obstructed in 70% of patients and allowed pulmonary embolism to recur through collaterals. The device that has been available for 20 years and remains in active use today is the Greenfield filter, with a reported longterm patency rate in excess of 95%. Contrary to the statement that filters are not in widespread use, more than 125,000 Greenfield filters have been inserted, and the frequency is increasing with percutaneous insertion. Although anticoagulation remains the foundation of treatment for venous thromboembolism, it may be contraindicated, cause serious complications, or fail to protect the patient from recurrent embolism, in which case a vena caval filter is the appropriate treatment. LAZAR
J.
GREENFIELD, M.D.
Professor and Chairman Department of Surgery University of Michigan
Three on Calmette A minor point in an otherwise interesting article about Albert Calmette by Elmer Bendiner
16
Hospital Practice December 15. 1992
(''Albert Calmette: A Vaccine and Its Vindication," HP. October 30). I am surprised that he skipped over streptomycin, isolated by the late Selman A. Waksman of Rutgers University in New Brunswick, N.J. It was in fact the first specific drug therapy for tuberculosis. SHELDON RUDANSKY, M.D.
Garden City, N.Y.
It was with fascination that I read ''Albert Calmette: A Vaccine and Its Vindication." I found the article riveting reading. I hope you have future articles that are so stimulating. It is amazing how much one can learn from the history of medicine and apply it to the present and to the future. I thank you for this most fascinating article on this most fascinating individual. ROBERT
F.
SACHA, D.O.
Cape Girardeau, Mo.
Has anyone thought to compile into a book/booklet your biographical vignettes as per your "Past and Present" series (e.g., Calmette, Yersin)? Makes great reading! R. S
0 B 0 C I N S K I, M.D.
Houston
The possiblltty qf separate publication of Elmer Bendiner's "Past and Present" articles has often come up. Th date, we have notfound a book publisher willing to undertake this, though we certainly believe it would be a worthwhile e.ffort.-ED
Wrong Impression In the September 30 issue, I was
cited by William E. Bolger and David W Kennedy in their article "Changing Concepts in Chronic Sinusitis." They mentioned that surgeons who are experienced have very low complication rates versus surgeons with less experience. I am named specifically, based on an article I wrote in 1987 that discussed complications of endoscopic intranasal ethmoidectomy. The impression is given that I represent less experienced surgeons with a high complication rate. I am in wholehearted agreement that as one moves along the learning curve, complication rates will appropriately decrease and that less experienced surgeons have to be very careful when undertaking intranasal endoscopic sinus surgery. However, I now have done over 1,500 ethmoidectomies, with a complication rate equivalent to any of those stated in the literature as acceptable. For my own benefit and for the benefit of my patients and students, I feel that the impression given in the article has to be corrected. I refer you to my updated article on complications of sinus surgery for further information. 1 J. A.
STANKIEWICZ, M.D.
Professor and Vice Chairman Department of OtolaryngologyHead and Neck Surgery Loyola University, Chicago
Reference 1. StankieWicz JA: Complications In endoscopic Intranasal ethmoidectomy: An update. Laryngoscope 99:686.1989
ISSN: 2154-8331 (Print) 2377-1003 (Online) Journal homepage: http://www.tandfonline.com/loi/ihop20
Letters To The Editor Lazar J. Greenfield M.D. , Sheldon Rudansky M.D., Robert F. Sacha D.O., R. Sobocinski M.D. & J. A. Stankiewicz M.D. To cite this article: Lazar J. Greenfield M.D. , Sheldon Rudansky M.D., Robert F. Sacha D.O., R. Sobocinski M.D. & J. A. Stankiewicz M.D. (1992) Letters To The Editor, Hospital Practice, 27:12, 16-16, DOI: 10.1080/21548331.1992.11705532 To link to this article: http://dx.doi.org/10.1080/21548331.1992.11705532
Published online: 17 May 2016.
Submit your article to this journal
View related articles
Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ihop20 Download by: [Monash University Library]
Date: 02 July 2016, At: 21:43
Letters to the Editor Antiembolic Filters: The State ofthe Art
Downloaded by [Monash University Library] at 21:43 02 July 2016
''A Non classic Case of Pulmo-
nary Embolism," by Elliot Rapaport (HP, September 15) contains a lot of useful information but unfortunately also contains some misinformation. In the discussion of follow-up, Rapaport mentions the use of an "umbrella" filter, which was the term applied to the MabinUddin device. It has not been marketed since the mid-1980s, because it became obstructed in 70% of patients and allowed pulmonary embolism to recur through collaterals. The device that has been available for 20 years and remains in active use today is the Greenfield filter, with a reported longterm patency rate in excess of 95%. Contrary to the statement that filters are not in widespread use, more than 125,000 Greenfield filters have been inserted, and the frequency is increasing with percutaneous insertion. Although anticoagulation remains the foundation of treatment for venous thromboembolism, it may be contraindicated, cause serious complications, or fail to protect the patient from recurrent embolism, in which case a vena caval filter is the appropriate treatment. LAZAR
J.
GREENFIELD, M.D.
Professor and Chairman Department of Surgery University of Michigan
Three on Calmette A minor point in an otherwise interesting article about Albert Calmette by Elmer Bendiner
16
Hospital Practice December 15. 1992
(''Albert Calmette: A Vaccine and Its Vindication," HP. October 30). I am surprised that he skipped over streptomycin, isolated by the late Selman A. Waksman of Rutgers University in New Brunswick, N.J. It was in fact the first specific drug therapy for tuberculosis. SHELDON RUDANSKY, M.D.
Garden City, N.Y.
It was with fascination that I read ''Albert Calmette: A Vaccine and Its Vindication." I found the article riveting reading. I hope you have future articles that are so stimulating. It is amazing how much one can learn from the history of medicine and apply it to the present and to the future. I thank you for this most fascinating article on this most fascinating individual. ROBERT
F.
SACHA, D.O.
Cape Girardeau, Mo.
Has anyone thought to compile into a book/booklet your biographical vignettes as per your "Past and Present" series (e.g., Calmette, Yersin)? Makes great reading! R. S
0 B 0 C I N S K I, M.D.
Houston
The possiblltty qf separate publication of Elmer Bendiner's "Past and Present" articles has often come up. Th date, we have notfound a book publisher willing to undertake this, though we certainly believe it would be a worthwhile e.ffort.-ED
Wrong Impression In the September 30 issue, I was
cited by William E. Bolger and David W Kennedy in their article "Changing Concepts in Chronic Sinusitis." They mentioned that surgeons who are experienced have very low complication rates versus surgeons with less experience. I am named specifically, based on an article I wrote in 1987 that discussed complications of endoscopic intranasal ethmoidectomy. The impression is given that I represent less experienced surgeons with a high complication rate. I am in wholehearted agreement that as one moves along the learning curve, complication rates will appropriately decrease and that less experienced surgeons have to be very careful when undertaking intranasal endoscopic sinus surgery. However, I now have done over 1,500 ethmoidectomies, with a complication rate equivalent to any of those stated in the literature as acceptable. For my own benefit and for the benefit of my patients and students, I feel that the impression given in the article has to be corrected. I refer you to my updated article on complications of sinus surgery for further information. 1 J. A.
STANKIEWICZ, M.D.
Professor and Vice Chairman Department of OtolaryngologyHead and Neck Surgery Loyola University, Chicago
Reference 1. StankieWicz JA: Complications In endoscopic Intranasal ethmoidectomy: An update. Laryngoscope 99:686.1989
